Table 4.

Recommended duration of bisphosphonate therapy for women [71,72].

Risk Stratification	Recommended Duration of Treatment
Women at high-risk, eg, •Fracture during treatment •Low hip T-score ≤ 2.5 •High fracture risk score with FRAX® •Previous major osteoporotic fracture •Older women > 70 years old with any of the above risk factors	Continue for up to 10 years (oral) or 6 years (intravenous) with periodic evaluation
Women not at high-risk	After 3–5 years of bisphosphonate therapy, a drug holiday of 2 years can be considered

FRAX®, Fracture Risk Assessment Tool.